**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use KISQALI FEMARA CO-PACK safely and effectively. See full prescribing information for KISQALI FEMARA CO-PACK.

KISQALI® FEMARA® CO-PACK (ribociclib tablets; letrozole tablets), co-packaged for oral use

Initial U.S. Approval: 2017

**RECENT MAJOR CHANGES**

Warnings and Precautions (5) 10/2022

**INDICATIONS AND USAGE**

KISQALI FEMARA CO-PACK, a co-packaged product containing ribociclib, a kinase inhibitor, and letrozole, an aromatase inhibitor, is indicated as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. (1)

**DOSEAGE AND ADMINISTRATION**

KISQALI FEMARA CO-PACK tablets are taken in combination orally with or without food. (2)

- KISQALI recommended starting dose: 600 mg orally (three 200 mg tablets) taken once daily for 21 consecutive days followed by 7 days off KISQALI treatment. (2.1)
- KISQALI dose interruption, reduction, and/or discontinuation may be required based on individual safety and tolerability. (2.2)
- FEMARA: 2.5 mg (one tablet) continuously for a 28-day cycle. (2.1)

**DOSE AND STRENGTHS**

Tablets:
- KISQALI: 200 mg (3)
- FEMARA: 2.5 mg (3)

**CONTRAINDICATIONS**

Known hypersensitivity to letrozole, or to any excipients of FEMARA. (4)

**WARNINGS AND PRECAUTIONS**

- Interstitial Lung Disease (ILD)/Pneumonitis: Patients treated with CDK 4/6 inhibitors should be monitored for pulmonary symptoms indicative of ILD/pneumonitis. Interrupt and evaluate patients with new or worsening respiratory symptoms suspected to be due to ILD/pneumonitis. Permanently discontinue KISQALI in patients with recurrent symptomatic or severe ILD/pneumonitis. (2.2, 5.1)
- Severe Cutaneous Adverse Reactions (SCARs): Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) can occur with KISQALI treatment. Permanently discontinue KISQALI in patients with SCARs or other life-threatening cutaneous reactions. (2.2, 5.2)
- QT Interval Prolongation: Monitor electrocardiograms (ECGs) and electrolytes prior to initiation of treatment with KISQALI. Repeat ECGs at approximately Day 14 of the first cycle and at the beginning of the second cycle, and as clinically indicated. Monitor electrolytes at the beginning of each cycle for 6 cycles, and as clinically indicated. Avoid using KISQALI with drugs known to prolong QT interval and/or strong CYP3A inhibitors. (2.2, 5.3, 7.1, 7.4)
- Hepatobiliary Toxicity: Increases in serum transaminase levels have been observed. Perform liver function tests (LFTs) before initiating treatment with KISQALI FEMARA CO-PACK. Monitor LFTs every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated. (2.2, 5.4)
- Neutropenia: Perform complete blood count (CBC) before initiating therapy with KISQALI FEMARA CO-PACK. Monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated. (2.2, 5.5)
- Embryo-Fetal Toxicity: Can cause fetal harm when administered to pregnant women. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during therapy. (5.6, 8.1, 8.3)

**ADVERSE REACTIONS**

Most common (incidence ≥ 20%) adverse reactions, including laboratory abnormalities, are leukocytes decreased, neutrophils decreased, hemoglobin decreased, lymphocytes decreased, alanine aminotransferase increased, aspartate aminotransferase increased, infections, nausea, fatigue, platelets decreased, diarrhea, headache, alopecia, vomiting, back pain, constipation, cough, rash, creatinine increased, and abdominal pain. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

**DRUG INTERACTIONS**

- CYP3A4 Inhibitors: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2.2, 7.1)
- CYP3A4 Inducers: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inducers. (7.2)
- CYP3A Substrates: The dose of sensitive CYP3A substrates with narrow therapeutic indices may need to be reduced when given concurrently with KISQALI FEMARA CO-PACK. (7.3)
- Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7.4)

**USE IN SPECIFIC POPULATIONS**

Lactation: Advise not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 8/2023
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

The KISQALI® FEMARA® CO-PACK is indicated as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

2 DOSAGE AND ADMINISTRATION

2.1 Dosing and Administration

The KISQALI FEMARA CO-PACK is comprised of ribociclib tablets copackaged with letrozole tablets, to provide a 28-day treatment regimen.

The KISQALI FEMARA CO-PACK should be coadministered, with or without food, as follows:

- **KISQALI**: The recommended starting dose for KISQALI is 600 mg (three 200 mg tablets) taken orally, once daily for 21 consecutive days followed by 7 days off KISQALI treatment resulting in a complete cycle of 28 days.

- **FEMARA**: 2.5 mg (one tablet) taken once daily throughout the 28-day cycle.

Patients should take their doses of KISQALI FEMARA CO-PACK at approximately the same time each day, preferably in the morning.

Pre/perimenopausal women, or men, treated with KISQALI FEMARA CO-PACK should be treated with a luteinizing hormone-releasing hormone (LHRH) agonist according to current clinical practice standards.

If the patient vomits after taking the dose or misses a dose, no additional dose should be taken that day. The next prescribed dose should be taken at the usual time. Tablets should be swallowed whole (tablets should not be chewed, crushed or split prior to swallowing). No tablet should be ingested if it is broken, cracked, or otherwise not intact.

For additional information on KISQALI® and FEMARA®, refer to the Full Prescribing Information for each product.

2.2 Dose Modifications

Dose Modifications for Adverse Reactions

The recommended dose modifications of KISQALI for adverse reactions are listed in Table 1. Dose modifications are not recommended for FEMARA when administered with KISQALI for the adverse reactions of KISQALI, including neutropenia, hepatobiliary toxicity, or QT prolongation [see Dosage and Administration (2)].

| Table 1: Recommended Dose Modification of KISQALI FEMARA CO-PACK for Adverse Reactions |
|-----------------------------------|-----------------------------------|-----------------------------------|
| Level                             | KISQALI Dose | Number of tablets | FEMARA Dose | Number of tablets |
| Starting dose                     | 600 mg/day   | three 200 mg tablets | 2.5 mg/day | one 2.5 mg tablet |
| First dose reduction              | 400 mg/day   | two 200 mg tablets  | 2.5 mg/day | one 2.5 mg tablet |
| Second dose reduction             | 200 mg/day*  | one 200 mg tablet  | 2.5 mg/day | one 2.5 mg tablet |

*If further dose reduction below 200 mg/day is required, discontinue KISQALI.

Tables 2, 3, 4, 5, 6, and 7 summarize recommendations for dose interruption, reduction, or discontinuation of KISQALI in the management of specific adverse reactions. Dose modifications of KISQALI FEMARA CO-PACK are recommended based on individual safety and tolerability.
### Table 2: Dose Modification and Management for Interstitial Lung Disease/Pneumonitis

<table>
<thead>
<tr>
<th>ILD/Pneumonitis [see Warnings and Precautions (5.1)]</th>
<th>Grade 1 (asymptomatic)</th>
<th>Grade 2 (symptomatic)</th>
<th>Grade 3 (severe symptomatic) or 4 (life-threatening)</th>
</tr>
</thead>
<tbody>
<tr>
<td>- No dose interruption or adjustment is required.</td>
<td>- Dose interruption until recovery to Grade $\leq 1$ then consider resuming KISQALI at the next lower dose level*.</td>
<td>- Discontinue KISQALI.</td>
<td></td>
</tr>
<tr>
<td>- Initiate appropriate medical therapy and monitor as clinically indicated.</td>
<td>- If Grade 2 recurs, discontinue KISQALI.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: ILD, interstitial lung disease.
Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
*An individualized benefit-risk assessment should be performed when considering resuming KISQALI.

### Table 3: Dose Modification and Management for Cutaneous Adverse Reactions, Including SCARs

<table>
<thead>
<tr>
<th>Cutaneous adverse reactions, including SCARs [see Warnings and Precautions (5.2)]</th>
<th>Grade 1 ($&lt; 10%$ body surface area (BSA) with active skin toxicity, no signs of systemic involvement)</th>
<th>Grade 2 (10%-30% BSA with active skin toxicity, no signs of systemic involvement)</th>
<th>Grade 3 (severe rash not responsive to medical management; $&gt; 30%$ BSA with active skin toxicity, signs of systemic involvement present; SJS*)</th>
<th>Grade 4 (any % BSA associated with extensive superinfection, with IV antibiotics indicated; life threatening consequences; TEN**)</th>
</tr>
</thead>
<tbody>
<tr>
<td>- No dose adjustment is required.</td>
<td>- Initiate appropriate medical therapy and monitor as clinically indicated.</td>
<td>Interrupt KISQALI until the etiology of the reaction has been determined.</td>
<td>If the etiology is a SCAR, permanently discontinue KISQALI.</td>
<td>Permanently discontinue KISQALI.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If the etiology is not a SCAR, interrupt dose until recovery to Grade $\leq 1$, then resume KISQALI at same dose level.</td>
<td>If the cutaneous adverse reaction still recurs at Grade 3, resume KISQALI at the next lower dose level.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>If the cutaneous adverse reaction still recurs at Grade 3, resume KISQALI at the next lower dose level.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BSA, body surface area; SCARs, severe cutaneous adverse reactions; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.
*SJS (Grade 3 and 4) is defined as skin sloughing covering $< 10\%$ BSA and 10%-30% BSA, respectively, with associated signs (e.g., erythema, purpura, epidermal detachment, and mucous membrane detachment).
**TEN (Grade 4) is defined as skin sloughing covering $\geq 30\%$ BSA with associated symptoms (e.g., erythema, purpura, epidermal detachment, and mucous membrane detachment).
Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Table 4: Dose Modification and Management of KISQALI for QT Prolongation

<table>
<thead>
<tr>
<th>ECGs with QTcF* &gt; 480 ms [see Warnings and Precautions (5.3)]</th>
<th>ECGs with QTcF &gt; 500 ms [see Warnings and Precautions (5.3)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Interrupt KISQALI treatment.</td>
<td>• Interrupt KISQALI treatment if QTcF greater than 500 ms.</td>
</tr>
<tr>
<td>• If QTcF prolongation resolves to &lt; 481 ms, resume treatment at the next lower dose level;</td>
<td>• If QTcF prolongation resolves to &lt; 481 ms, resume treatment at the next lower dose level.</td>
</tr>
<tr>
<td>• If QTcF ≥ 481 ms recurs, interrupt dose until QTcF resolves to &lt; 481 ms; then resume KISQALI at next lower dose level.</td>
<td>Permanently discontinue KISQALI if QTcF interval prolongation is either greater than 500 ms or greater than 60 ms change from baseline AND associated with any of the following: Torsades de Pointes, polymorphic ventricular tachycardia, unexplained syncope, or signs/symptoms of serious arrhythmia.</td>
</tr>
</tbody>
</table>

Electrocardiograms (ECGs) should be assessed prior to initiation of treatment. Repeat ECGs at approximately Day 14 of the first cycle and at the beginning of the second cycle, and as clinically indicated. In case of (QTcF) prolongation at any given time during treatment, more frequent ECG monitoring is recommended.

*QTcF = QT interval corrected by Fridericia’s formula.

Table 5: Dose Modification and Management of KISQALI for Hepatobiliary Toxicity

<table>
<thead>
<tr>
<th>Grade 1 (&gt; ULN – 3 x ULN)</th>
<th>Grade 2 (&gt; 3 to 5 x ULN)</th>
<th>Grade 3 (&gt; 5 to 20 x ULN)</th>
<th>Grade 4 (&gt; 20 x ULN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No dose adjustment is required.</td>
<td>Baseline* at &lt; Grade 2: Dose interruption until recovery to ≤ baseline* grade, and then resume KISQALI at same dose level.</td>
<td>Dose interruption until recovery to ≤ baseline* grade, and then resume at next lower dose level.</td>
<td>Discontinue KISQALI.</td>
</tr>
<tr>
<td>[see Warnings and Precautions (5.4)]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Combined elevations in AST and/or ALT WITH total bilirubin increase, in the absence of cholestasis [see Warnings and Precautions (5.4)]**

If patients develop ALT and/or AST > 3 x ULN along with total bilirubin > 2 x ULN irrespective of baseline grade, discontinue KISQALI.

Perform Liver Function Tests (LFTs) before initiating treatment with KISQALI. Monitor LFTs every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated.

If Grade ≥ 2 abnormalities are noted, more frequent monitoring is recommended.

**Abbreviations:** AST, aspartate aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal.

*Baseline = prior to treatment initiation.

Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
<table>
<thead>
<tr>
<th>Grade 1 or 2 (ANC 1000/mm³ – &lt; LLN)</th>
<th>Grade 3 (ANC 500 - &lt; 1000/mm³)</th>
<th>Grade 3 Febrile* Neutropenia</th>
<th>Grade 4 (ANC &lt; 500/mm³)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutropenia [see Warnings and Precautions (5.5)]</td>
<td>No dose adjustment is required. Dose interruption until recovery to Grade ≤ 2. Resume KISQALI at the same dose level. If toxicity recurs at Grade 3, dose interruption until recovery, then resume KISQALI at the next lower dose level.</td>
<td>Dose interruption until recovery of neutropenia to Grade ≤ 2. Resume KISQALI at the next lower dose level.</td>
<td>Dose interruption until recovery to Grade ≤ 2. Resume KISQALI at the next lower dose level.</td>
</tr>
</tbody>
</table>

Perform complete blood counts (CBCs) before initiating treatment with KISQALI. Monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated.

Abbreviations: ANC, absolute neutrophil count; LLN, lower limit of normal.

*Grade 3 neutropenia with single episode of fever > 38.3°C (or) above 38°C for more than one hour and/or concurrent infection. Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

<table>
<thead>
<tr>
<th>Grade 1 or 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other toxicities</td>
<td>No dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.</td>
<td>Dose interruption until recovery to Grade ≤ 1 then resume KISQALI at same dose level. If Grade 3 recurs, resume KISQALI at the next lower dose level.</td>
</tr>
</tbody>
</table>

*Excluding interstitial lung disease (ILD)/pneumonitis, cutaneous adverse reactions, including severe cutaneous adverse reactions (SCARs), QT interval prolongation, hepatobiliary toxicity, and neutropenia. Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

**Dose Modification for Use with Strong CYP3A Inhibitors**

Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors and consider an alternative concomitant medication with less potential for CYP3A inhibition [see Drug Interactions (7.1)]. If a strong CYP3A inhibitor must be coadministered, reduce the KISQALI dose to 400 mg once daily. If the strong inhibitor is discontinued, change the KISQALI dose (after at least 5 half-lives of the strong CYP3A inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].

**Dose Modification for Hepatic Impairment**

No dose adjustment of KISQALI is necessary in patients with mild hepatic impairment (Child-Pugh class A). The recommended starting dose is 400 mg KISQALI once daily for patients with moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C) [see Clinical Pharmacology (12.3)].

No dose adjustment of FEMARA is necessary in patients with mild (Child-Pugh class A) to moderate (Child-Pugh class B) hepatic impairment. The dose of FEMARA in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50% [see Clinical Pharmacology (12.3)]. The recommended dose of FEMARA for such patients is 2.5 mg administered every other day. The effect of hepatic impairment on FEMARA exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined [see Clinical Pharmacology (12.3)].
Dose Modification for Renal Impairment

No dose adjustment is necessary in patients with mild or moderate renal impairment. The recommended starting dose is 200 mg KISQALI once daily for patients with severe renal impairment [see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)].

No dosage adjustment of FEMARA is required for patients with renal impairment if creatinine clearance is greater than or equal to 10 mL/min [see Clinical Pharmacology (12.3)].

3 DOSAGE FORMS AND STRENGTHS
KISQALI FEMARA CO-PACK is KISQALI (ribociclib) tablets copackaged with FEMARA (letrozole) tablets.
- Tablets 200 mg ribociclib (equivalent to 254.40 mg ribociclib succinate): Film-coated, light greyish violet, round, curved with beveled edges, debossed with “RIC” on one side and “NVR” on the other side.
- Tablets 2.5 mg letrozole: Dark yellow, film-coated, round, slightly biconvex, with beveled edges (imprinted with the letters “FV” on one side and “CG” on the other side).

4 CONTRAINDICATIONS
Known hypersensitivity to the active substance (letrozole), or to any of the excipients of FEMARA. Refer to FEMARA Prescribing Information.

5 WARNINGS AND PRECAUTIONS
5.1 Interstitial Lung Disease/Pneumonitis
Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with KISQALI and other CDK4/6 inhibitors.

Across clinical trials (MONALEESA-2, MONALEESA-7), 1.2% of KISQALI-treated patients had ILD/pneumonitis of any grade and 0.3% had Grade 3 or 4. Additional cases of ILD/pneumonitis have been observed in the postmarketing setting, with fatalities reported [see Adverse Reactions (6.2)].

Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis which may include hypoxia, cough, and dyspnea. In patients who have new or worsening respiratory symptoms suspected to be due to ILD or pneumonitis, interrupt KISQALI immediately and evaluate the patient. Permanently discontinue KISQALI in patients with recurrent symptomatic or severe ILD/pneumonitis [see Dosage and Administration (2.2)]. Refer to the Full Prescribing Information for KISQALI®.

5.2 Severe Cutaneous Adverse Reactions
Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS), can occur in patients treated with KISQALI [see Adverse Reactions (6.2)].

If signs or symptoms of SCARs occur, interrupt KISQALI until the etiology of the reaction has been determined [see Dosage and Administration (2.2)]. Early consultation with a dermatologist is recommended to ensure greater diagnostic accuracy and appropriate management.

If SJS, TEN, or DiHS/DRESS is confirmed, permanently discontinue KISQALI. Do not reintroduce KISQALI in patients who have experienced SCARs during KISQALI treatment.

5.3 QT Interval Prolongation
KISQALI has been shown to prolong the QT interval in a concentration-dependent manner [see Clinical Pharmacology (12.2)]. Based on the observed QT prolongation during treatment, KISQALI may require dose interruption, reduction or discontinuation as described in Table 4 [see Dosage and Administration (2.2), Drug Interactions (7.4)].

In MONALEESA-2 and MONALEESA-7, in patients with advanced or metastatic breast cancer who received the combination of KISQALI plus an aromatase inhibitor, 7 out of 574 patients (1%) had > 500 ms post-baseline QTcF value, and 29 out of 574 patients (5%) had a > 60 ms increase from baseline in QTcF intervals.

These ECG changes were reversible with dose interruption and the majority occurred within the first four weeks of treatment. There were no reported cases of Torsades de Pointes.
In MONALEESA-2, there was one (0.3%) sudden death in a patient with Grade 3 hypokalemia and Grade 2 QT prolongation. No cases of sudden death were reported in MONALEESA-7 [see Adverse Reactions (6)].

Assess ECG prior to initiation of treatment. Initiate treatment with KISQALI FEMARA CO-PACK only in patients with QTcF values less than 450 ms. Repeat ECG at approximately Day 14 of the first cycle and the beginning of the second cycle, and as clinically indicated.

Monitor serum electrolytes (including potassium, calcium, phosphorous, and magnesium) prior to the initiation of treatment, at the beginning of the first 6 cycles, and as clinically indicated. Correct any abnormality before starting KISQALI FEMARA CO-PACK therapy [see Dosage and Administration (2.2)].

Avoid the use of KISQALI FEMARA CO-PACK in patients who already have or who are at significant risk of developing QT prolongation, including patients with:

- long QT syndrome
- uncontrolled or significant cardiac disease, including recent myocardial infarction, congestive heart failure, unstable angina and bradyarrhythmias
- electrolyte abnormalities

Avoid using KISQALI FEMARA CO-PACK with drugs known to prolong QT interval and/or strong CYP3A inhibitors as this may lead to prolongation of the QTcF interval [see Drug Interactions (7.4), Clinical Pharmacology (12.3)].

Based on the observed QT prolongation during treatment, KISQALI may require dose interruption, reduction, or discontinuation as described in Table 4 [see Dosage and Administration (2.2), Drug Interactions (7.4)]. KISQALI is not indicated for concomitant use with tamoxifen. Refer to the Full Prescribing Information for KISQALI®.

5.4 Hepatobiliary Toxicity

In MONALEESA-2 and MONALEESA-7, increases in transaminases were observed, with Grade 3 or 4 increases in alanine aminotransferase (ALT) (11% vs. 2%) and aspartate aminotransferase (AST) (8% vs. 2%) reported in the KISQALI plus aromatase inhibitor and placebo arms, respectively.

Among the patients who had Grade ≥ 3 ALT/AST elevation, the median time-to-onset was 111 days for the KISQALI plus aromatase inhibitor treatment group. The median time to resolution to Grade ≤ 2 was 22 days in the KISQALI plus aromatase inhibitor treatment group.

Concurrent elevations in ALT or AST greater than three times the upper limit of normal (ULN) and total bilirubin greater than two times the ULN, with normal alkaline phosphatase, in the absence of cholestasis occurred in 4 (1%) patients in MONALEESA-2 and all patients recovered after discontinuation of KISQALI. No cases occurred in MONALEESA-7.

Perform liver function tests (LFTs) before initiating therapy with KISQALI FEMARA CO-PACK. Monitor LFTs every 2 weeks for first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated [see Dosage and Administration (2.2)].

Based on the severity of the transaminase elevations, KISQALI may require dose interruption, reduction, or discontinuation as described in Table 5 (Dose Modification and Management for Hepatobiliary Toxicity) [see Dosage and Administration (2.2)]. Recommendations for patients who have elevated AST/ALT Grade ≥ 3 at baseline have not been established.

5.5 Neutropenia

In MONALEESA-2 and MONALEESA-7, neutropenia was the most frequently reported adverse reaction (79%) and a Grade 3/4 decrease in neutrophil count (based on laboratory findings) was reported in 66% of patients receiving KISQALI plus an aromatase inhibitor. Among the patients who had Grade 2, 3, or 4 neutropenia, the median time to Grade ≥ 2 neutropenia was 16 days. The median time to resolution of Grade ≥ 3 (to normalization or Grade < 3) was 15 days in the KISQALI plus aromatase inhibitor treatment group. Febrile neutropenia was reported in 2% of patients receiving KISQALI plus an aromatase inhibitor. Treatment discontinuation due to neutropenia was 1%.

Perform CBC before initiating therapy with KISQALI FEMARA CO-PACK. Monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated.

Based on the severity of the neutropenia, KISQALI may require dose interruption, reduction or discontinuation as described in Table 6 [see Dosage and Administration (2.2)].
5.6 Embryo-Fetal Toxicity

Based on findings from animal studies and the mechanisms of action, KISQALI FEMARA CO-PACK can cause fetal harm when administered to a pregnant woman.

In animal reproduction studies, administration of ribociclib to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicities at maternal exposures that were 0.6 and 1.5 times the human clinical exposure, respectively, based on area under the curve (AUC).

Letrozole caused embryo-fetal toxicities in rats and rabbits at maternal exposures that were below the maximum recommended human dose (MRHD) on a mg/m² basis.

Advise pregnant women of the potential risk to a fetus. Advise women of reproductive potential to use effective contraception during therapy with KISQALI FEMARA CO-PACK and for at least 3 weeks after the last dose [see Use in Specific Populations (8.1, 8.3), Clinical Pharmacology (12.1)].

6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the labeling:

- Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5.1)]
- Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.2)]
- QT Interval Prolongation [see Warnings and Precautions (5.3)]
- Hepatobiliary Toxicity [see Warnings and Precautions (5.4)]
- Neutropenia [see Warnings and Precautions (5.5)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to KISQALI in 582 patients in MONALEESA-2 and MONALEESA-7. Among these patients who received KISQALI, 80% were exposed for 6 months or longer and 65% were exposed for greater than one year. In this pooled safety population, the most common (≥ 20%) adverse reactions, including laboratory abnormalities, were leukocytes decreased (94%), neutrophils decreased (94%), hemoglobin decreased (72%), lymphocytes decreased (59%), alanine aminotransferase increased (53%), aspartate aminotransferase increased (53%), infections (46%), nausea (46%), fatigue (36%), platelets decreased (34%), diarrhea (33%), headache (29%), alopecia (29%), vomiting (29%), back pain (25%), constipation (25%), cough (24%), rash (22%), creatinine increased (20%), and abdominal pain (20%).

MONALEESA-2: KISQALI in Combination with Letrozole

Postmenopausal Women with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer for Initial Endocrine-Based Therapy

The safety of KISQALI was evaluated in MONALEESA-2, a clinical study of 668 postmenopausal women receiving KISQALI plus letrozole or placebo plus letrozole [see Clinical Studies (14)]. The median duration of exposure to KISQALI plus letrozole was 13 months with 58% of patients exposed for ≥ 12 months.

Serious adverse reactions occurred in 21% of patients who received KISQALI plus letrozole. Serious adverse reactions in ≥1% of patients receiving KISQALI plus letrozole included abdominal pain (1.5%), vomiting (1.5%), constipation (1.2%), nausea (1.2%), anemia (1.2%), febrile neutropenia (1.2%), dyspnea (1.2%), and alanine aminotransferase increased (1.2%).

Permanent discontinuation of both KISQALI and letrozole due to an adverse reaction occurred in 7% of patients. Permanent discontinuation of KISQALI alone occurred in 7% of patients. Adverse reactions which resulted in permanent discontinuation of both KISQALI and letrozole in ≥ 2% of patients were alanine aminotransferase increased (5%), aspartate aminotransferase increased (3%), and vomiting (2%).
Dosage interruptions of both KISQALI and letrozole due to an adverse reaction occurred in 71% of patients. Adverse reactions which required dosage interruption in ≥ 5% of patients included neutropenia (39%), neutrophils decreased (12%), vomiting (6%), nausea (5%), alanine aminotransferase increased (5%), and leukocytes decreased (5%).

Dose reductions due to adverse reaction occurred in 45% of patients receiving KISQALI plus letrozole. Adverse reactions which required dose reductions in ≥ 2% of patients included neutropenia (24%), neutrophils decreased (8%), and alanine aminotransferase increased (3%).

Antiemetics and antidiarrheal medications were used to manage symptoms as clinically indicated.

The most common (≥ 20% on the KISQALI arm and ≥ 2% higher than placebo) adverse reactions were neutrophils decreased, leukocytes decreased, hemoglobin decreased, nausea, lymphocytes decreased, alanine aminotransferase increased, aspartate aminotransferase increased, fatigue, diarrhea, alopecia, vomiting, platelets decreased, constipation, headache, and back pain.

The most common ARs (reported at a frequency ≥ 20% on the KISQALI arm and ≥ 2% higher than placebo) were neutropenia, nausea, fatigue, diarrhea, leukopenia, alopecia, vomiting, constipation, headache, and back pain.

Table 8 summarizes the adverse reactions in MONALEESA-2.

Table 8: Adverse Reactions (≥ 10% and ≥ 2% Higher Than Placebo Arm) in MONALEESA-2

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>KISQALI + Letrozole (n = 334)</th>
<th>Placebo + Letrozole (n = 330)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades (%)</td>
<td>Grade 3 or 4 (%)</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>52</td>
<td>2.4</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>35</td>
<td>1.2</td>
</tr>
<tr>
<td>Vomiting</td>
<td>29</td>
<td>3.6</td>
</tr>
<tr>
<td>Constipation</td>
<td>25</td>
<td>1.2</td>
</tr>
<tr>
<td>Stomatitis</td>
<td>12</td>
<td>0.3</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>11</td>
<td>1.2</td>
</tr>
<tr>
<td>General disorders and administration-site conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>37</td>
<td>2.4</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>13</td>
<td>0.3</td>
</tr>
<tr>
<td>Edema peripheral</td>
<td>12</td>
<td>0</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td>33</td>
<td>0</td>
</tr>
<tr>
<td>Rash</td>
<td>17</td>
<td>0.6</td>
</tr>
<tr>
<td>Pruritus</td>
<td>14</td>
<td>0.6</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>22</td>
<td>0.3</td>
</tr>
<tr>
<td>Insomnia</td>
<td>12</td>
<td>0.3</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back pain</td>
<td>20</td>
<td>2.1</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>19</td>
<td>1.5</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnea</td>
<td>12</td>
<td>1.2</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary tract infections</td>
<td>11</td>
<td>0.6</td>
</tr>
</tbody>
</table>

Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

1Only includes Grade 3 adverse reactions.
Clinically relevant adverse reactions in < 10% of patients in MONALEESA-2 receiving KISQALI plus letrozole included interstitial lung disease (0.3%), lung infiltration (0.3%), pneumonitis (0.3%), and pulmonary fibrosis (0.6%). Table 9 summarizes the laboratory abnormalities in MONALEESA-2.

Table 9: Select Laboratory Abnormalities (≥ 10%) in Patients in MONALEESA-2 Who Received KISQALI Plus Letrozole

<table>
<thead>
<tr>
<th>Laboratory abnormality</th>
<th>KISQALI + Letrozole (n = 334)</th>
<th>Placebo + Letrozole (n = 330)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades (%)</td>
<td>Grade 3 or 4 (%)</td>
</tr>
<tr>
<td>Hematology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukocytes decreased</td>
<td>93</td>
<td>34</td>
</tr>
<tr>
<td>Neutrophils decreased</td>
<td>93</td>
<td>60</td>
</tr>
<tr>
<td>Hemoglobin decreased</td>
<td>57</td>
<td>1.8</td>
</tr>
<tr>
<td>Lymphocytes decreased</td>
<td>51</td>
<td>14</td>
</tr>
<tr>
<td>Platelets decreased</td>
<td>29</td>
<td>0.9</td>
</tr>
<tr>
<td>Chemistry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alanine aminotransferase</td>
<td>46</td>
<td>10</td>
</tr>
<tr>
<td>Aspartate aminotransferase</td>
<td>44</td>
<td>7</td>
</tr>
<tr>
<td>Creatinine increased</td>
<td>20</td>
<td>0.6</td>
</tr>
<tr>
<td>Phosphorous decreased</td>
<td>13</td>
<td>5</td>
</tr>
<tr>
<td>Potassium decreased</td>
<td>11</td>
<td>1.2</td>
</tr>
</tbody>
</table>

Adverse reactions listed are based on the data of KISQALI in combination with letrozole (FEMARA). For the complete list of known ARs with KISQALI or FEMARA, see the Full Prescribing Information of KISQALI or FEMARA.

Bone Effects

In MONALEESA-2, with a median duration of safety follow-up of 20.1 months, 12 patients (4%) in the ribociclib plus letrozole arm and 18 patients (6%) in the placebo plus letrozole arm experienced fractures. Osteoporosis (all Grades) was experienced in three patients (0.9%) in the ribociclib plus letrozole arm and 2 patients (0.6%) in the placebo plus letrozole arm.

MONALEESA-7: KISQALI in Combination with an Aromatase Inhibitor

Pre/perimenopausal Patients with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer for Initial Endocrine-Based Therapy

The safety of KISQALI was evaluated in MONALEESA-7, a clinical study of 672 pre/perimenopausal patients with HR-positive, HER2-negative advanced or metastatic breast cancer receiving either KISQALI plus non-steroidal aromatase inhibitors (NSAIs) or tamoxifen plus goserelin or placebo plus NSAII or tamoxifen plus goserelin [see Clinical Studies (14)]. The median duration of exposure on the KISQALI plus a NSAII arm was 15.2 months with 66% of patients exposed for ≥ 12 months. The safety data reported below are based on 495 pre/perimenopausal patients receiving KISQALI plus NSAII plus goserelin or placebo plus NSAII plus goserelin.

Serious adverse reactions occurred in 17% of patients who received KISQALI plus NSAII plus goserelin. Serious adverse reactions in ≥ 1% of patients receiving KISQALI plus NSAII plus goserelin included drug-induced liver injury (1.6%), abdominal pain (1.2%), dyspnea (1.2%), febrile neutropenia (1.2%), and back pain (1.2%).

Permanent discontinuation of both KISQALI and NSAII due to an adverse reaction occurred in 3% of patients. Permanent discontinuation of KISQALI alone occurred in 3% patients. Adverse reactions which resulted in permanent discontinuation of both KISQALI and NSAII in ≥ 2% of patients were alanine aminotransferase increased (2%), and aspartate aminotransferase increased (2%).

Dosage interruptions of KISQALI plus NSAII plus goserelin due to an adverse reaction occurred in 73% of patients. Adverse reactions which required dosage interruption in ≥ 5% of patients included neutropenia (41%), neutrophils decreased (26%), and leukocytes decreased (6%).

Dose reductions due to ARs occurred in 33% of patients receiving KISQALI plus NSAII plus goserelin. Adverse reactions which required dose reductions in ≥ 2% of patients included neutropenia (17%), neutrophils decreased (5%), and alanine aminotransferase increased (2%).
The most common (≥ 20% on the KISQALI arm and ≥ 2% higher than placebo) adverse reactions, including laboratory abnormalities, were leukocytes decreased, neutrophils decreased, hemoglobin decreased, lymphocytes decreased, gamma-glutamyl transferase increased, aspartate aminotransferase increased, infections, arthralgia, alanine aminotransferase increased, nausea, platelets decreased, and alopecia.

Table 10 summarizes the adverse reactions in MONALEESA-7.

Table 10: Adverse Reactions (≥ 10% and ≥ 2% Higher Than Placebo Arm) in MONALEESA-7 (NSAI)

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>KISQALI + NSAI + Goserelin (n = 248)</th>
<th>Placebo + NSAI + Goserelin (n = 247)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades (%)</td>
<td>Grade 3 or 4 (%)</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infections¹,²</td>
<td>36</td>
<td>1.6</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia²</td>
<td>34</td>
<td>0.8</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea²</td>
<td>32</td>
<td>0</td>
</tr>
<tr>
<td>Constipation²</td>
<td>16</td>
<td>0</td>
</tr>
<tr>
<td>Stomatitis²</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia²</td>
<td>21</td>
<td>0</td>
</tr>
<tr>
<td>Rash²</td>
<td>17</td>
<td>0.4</td>
</tr>
<tr>
<td>Pruritus²</td>
<td>11</td>
<td>0</td>
</tr>
<tr>
<td>General disorders and administration-site conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pyrexia²</td>
<td>17</td>
<td>0.8</td>
</tr>
<tr>
<td>Pain in extremity²</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough²</td>
<td>15</td>
<td>0</td>
</tr>
</tbody>
</table>

Abbreviation: NSAI, non-steroidal aromatase inhibitor.
Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
¹Infections: urinary tract infections; respiratory tract infections; gastroenteritis; sepsis (< 1%).
²Only includes Grade 3 adverse reactions.

Clinically relevant adverse reactions in < 10% of patients in MONALEESA-7 receiving KISQALI plus NSAI included thrombocytopenia (9%), dry skin (9%), oropharyngeal pain (7%), dyspepsia (5%), lacrimation increased (4%), dry eye (4%), vitiligo (3%), hypocalcemia (2%), blood bilirubin increased (1%), syncope (0.4%), and pneumonitis (0.4%).

Table 11: Select Laboratory Abnormalities (≥ 10%) in Patients in MONALEESA-7 Who Received KISQALI Plus NSAI Plus Goserelin

<table>
<thead>
<tr>
<th>Laboratory abnormality</th>
<th>KISQALI + NSAI + Goserelin (n = 248)</th>
<th>Placebo + NSAI + Goserelin (n = 247)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades (%)</td>
<td>Grade 3 or 4 (%)</td>
</tr>
<tr>
<td>Hematology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukocytes decreased</td>
<td>93</td>
<td>36</td>
</tr>
<tr>
<td>Neutrophils decreased</td>
<td>92</td>
<td>63</td>
</tr>
<tr>
<td>Hemoglobin decreased</td>
<td>84</td>
<td>2.4</td>
</tr>
<tr>
<td>Lymphocytes decreased</td>
<td>55</td>
<td>14</td>
</tr>
<tr>
<td>Platelets decreased</td>
<td>26</td>
<td>0.4</td>
</tr>
</tbody>
</table>
**Chemistry**

<table>
<thead>
<tr>
<th></th>
<th>42</th>
<th>7</th>
<th>42</th>
<th>9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gamma-glutamyl transferase increased</td>
<td>37</td>
<td>4.8</td>
<td>35</td>
<td>1.6</td>
</tr>
<tr>
<td>Aspartate aminotransferase increased</td>
<td>33</td>
<td>6</td>
<td>31</td>
<td>1.6</td>
</tr>
<tr>
<td>Alanine aminotransferase increased</td>
<td>14</td>
<td>1.6</td>
<td>11</td>
<td>0.8</td>
</tr>
<tr>
<td>Phosphorous decreased</td>
<td>11</td>
<td>1.2</td>
<td>14</td>
<td>1.2</td>
</tr>
<tr>
<td>Potassium decreased</td>
<td>10</td>
<td>0.4</td>
<td>10</td>
<td>0.4</td>
</tr>
<tr>
<td>Glucose serum decreased</td>
<td>8</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

Adverse reactions listed are based on the data of KISQALI in combination with NSAI [anastrozole or letrozole (FEMARA)]. For the complete list of known adverse reactions with KISQALI or FEMARA, see the Full Prescribing Information of KISQALI or FEMARA.

**Bone Effects**

In MONALEESA-7, with a median duration of safety follow-up of 26.5 months, 4 patients (2%) in the ribociclib plus NSAI subgroup and 7 patients (3%) in the placebo plus NSAI subgroup experienced fractures. No osteoporosis (all Grades) was reported in the ribociclib plus NSAI subgroup, and 1 patient (0.4%) experienced osteoporosis in the placebo plus NSAI subgroup.

**COMPLEMENT-1: KISQALI in Combination with Letrozole and Goserelin or Leuprolide**

*Men with HR-positive, HER2-negative Advanced Breast Cancer for Initial Endocrine-Based Therapy*

The safety of KISQALI in combination with letrozole was evaluated in men (n = 39) in an open-label, multicenter clinical study for the treatment of adult patients with HR-positive, HER2-negative, advanced breast cancer who received no prior hormonal therapy for advanced disease (COMPLEMENT-1) [see Clinical Studies (14)].

The median duration of exposure to KISQALI was 20.8 months (range, 0.5 to 30.6 months).

Other adverse reactions occurring in men treated with KISQALI plus letrozole and goserelin or leuprolide were similar to those occurring in women treated with KISQALI plus endocrine therapy.

**6.2 Postmarketing Experience**

The following adverse events have been reported during post-approval use of KISQALI. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Respiratory disorders:** Interstitial lung disease/pneumonitis

**Skin and subcutaneous tissue disorders:** Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia, and systemic symptoms (DRESS).

**7 DRUG INTERACTIONS**

**Ribociclib**

**7.1 Drugs That May Increase Ribociclib Plasma Concentrations**

CYP3A4 Inhibitors

Coadministration of a strong CYP3A4 inhibitor (ritonavir) increased ribociclib exposure in healthy subjects by 3.2-fold [see Clinical Pharmacology (12.3)]. Avoid concomitant use of strong CYP3A inhibitors (e.g., boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, and voriconazole) and consider alternative concomitant medications with less potential for CYP3A inhibition.

If coadministration of KISQALI with a strong CYP3A inhibitor cannot be avoided, reduce the dose of KISQALI to 400 mg once daily [see Dosage and Administration (2.2)].

Instruct patients to avoid grapefruit or grapefruit juice, which are known to inhibit cytochrome CYP3A enzymes and may increase the exposure to ribociclib [see Patient Counseling Information (17)].
7.2 Drugs That May Decrease Ribociclib Plasma Concentrations

CYP3A4 Inducers

Coadministration of a strong CYP3A4 inducer (rifampin) decreased the plasma exposure of ribociclib in healthy subjects by 89% [see Clinical Pharmacology (12.3)]. Avoid concomitant use of strong CYP3A inducers and consider an alternate concomitant medication with no or minimal potential to induce CYP3A (e.g., phenytoin, rifampin, carbamazepine, and St. John’s wort [Hypericum perforatum]).

7.3 Effect of KISQALI on Other Drugs

CYP3A Substrates with Narrow Therapeutic Index

Coadministration of midazolam (a sensitive CYP3A4 substrate) with multiple doses of KISQALI (400 mg) increased the midazolam exposure by 3.8-fold in healthy subjects, compared with administration of midazolam alone [see Clinical Pharmacology (12.3)]. KISQALI given at the clinically relevant dose of 600 mg is predicted to increase the midazolam AUC by 5.2-fold. Therefore, caution is recommended when KISQALI is administered with CYP3A substrates with a narrow therapeutic index. The dose of a sensitive CYP3A substrate with a narrow therapeutic index, including but not limited to alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus may need to be reduced as ribociclib can increase their exposure.

7.4 Drugs That Prolong the QT Interval

Avoid coadministration of KISQALI with medicinal products with a known potential to prolong QT, such as antiarrhythmic medicines (including, but not limited to amiodarone, disopyramide, procainamide, quinidine, and sotalol), and other drugs that are known to prolong the QT interval (including, but not limited to, chloroquine, halofantrine, clarithromycin, haloperidol, methadone, moxifloxacin, bepridil, pimozide, and ondansetron) [see Warnings and Precautions (5.1), Clinical Pharmacology (12.3)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on findings from animal studies and the mechanisms of action, KISQALI FEMARA CO-PACK can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus.

In animal reproduction studies, administration of ribociclib to pregnant animals during organogenesis resulted in increased incidences of post-implantation loss and reduced fetal weights in rats and increased incidences of fetal abnormalities in rabbits at exposures 0.6 or 1.5 times the exposure in humans, respectively, at the highest recommended dose of 600 mg/day based on AUC (see Data).

In animal reproduction studies, administration of letrozole to pregnant animals during organogenesis resulted in increased post-implantation pregnancy loss and resorptions, fewer live fetuses, and fetal malformations affecting the renal and skeletal systems in rats and rabbits at doses approximately 0.1 times the daily MRHD on a mg/m² basis (see Data).

The background risk of major birth defects for the indicated population is unknown. However, the background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies in the U.S. general population.

Data

Animal Data - Ribociclib

In embryo-fetal development studies in rats and rabbits, pregnant animals received oral doses of ribociclib up to 1000 mg/kg/day and 60 mg/kg/day, respectively, during the period of organogenesis.

In rats, 300 mg/kg/day resulted in reduced maternal body weight gain and reduced fetal weights accompanied by skeletal changes related to the lower fetal weights. There were no significant effects on embryo-fetal viability or fetal morphology at 50 or 300 mg/kg/day.

In rabbits at doses ≥ 30 mg/kg/day, there were adverse effects on embryo-fetal development, including increased incidences of fetal abnormalities (malformations and external, visceral, and skeletal variants) and fetal growth (lower fetal weights). These findings included reduced/small lung lobes, additional vessel on the descending aorta, additional vessel
on the aortic arch, small eyes, diaphragmatic hernia, absent accessory lobe or (partly) fused lung lobes, reduced/small accessory lung lobe, extra/rudimentary 13th ribs, misshapen hyoid bone, bent hyoid bone alae and reduced number of phalanges in the pollex. There was no evidence of increased incidence of embryo-fetal mortality. There was no maternal toxicity observed at 30 mg/kg/day.

At 300 mg/kg/day in rats and 30 mg/kg/day in rabbits, the maternal systemic exposures (AUC) were approximately 0.6 and 1.5 times, respectively, the exposure in patients at the highest recommended dose of 600 mg/day.

Animal Data - Letrozole

In a fertility and early embryonic developmental toxicity study in female rats, oral administration of letrozole starting 2 weeks before mating until pregnancy day 6 resulted in an increase in pre-implantation loss at doses ≥ 0.003 mg/kg/day (approximately 0.01 times the MRHD on a mg/m² basis).

In an embryo-fetal developmental toxicity study in rats, daily administration of oral letrozole during the period of organogenesis at doses ≥ 0.003 mg/kg (approximately 0.01 times the MRHD on a mg/m² basis) resulted in embryo-fetal toxicity, including intrauterine mortality, increased resorptions and postimplantation loss, decreased numbers of live fetuses and fetal anomalies, including absence and shortening of renal papilla, dilation of ureter, edema and incomplete ossification of frontal skull and metatarsals. Letrozole was teratogenic to rats at a dose of 0.03 mg/kg (approximately 0.1 times the MRHD on a mg/m² basis) and caused fetal domed head and cervical/centrum vertebral fusion.

In an embryo-fetal developmental toxicity study in rabbits, daily administration of oral letrozole during the period of organogenesis at doses ≥ 0.002 mg/kg (approximately 0.01 the MRHD on a mg/m² basis) resulted in embryo-fetal toxicity, including increased resorptions, increased postimplantation loss and decreased numbers of live fetuses. Fetal anomalies included incomplete ossification of the skull, sternebrae, and fore- and hind legs.

8.2 Lactation

Risk Summary

It is not known if ribociclib and letrozole are present in human milk. There are no data on the effects of ribociclib and/or letrozole on the breastfed infant or milk production. Ribociclib and its metabolites readily passed into the milk of lactating rats (see Data). Exposure of lactating rats to letrozole was associated with an impaired reproductive performance of the male offspring (see Data). Because of the potential for serious adverse reactions in breastfed infants from KISQALI FEMARA CO-PACK, advise lactating women not to breastfeed while taking KISQALI FEMARA CO-PACK and for at least 3 weeks after the last dose.

Data

Animal Data - Ribociclib

In lactating rats administered a single dose of 50 mg/kg, exposure to ribociclib was 3.56-fold higher in milk compared to maternal plasma.

Animal Data - Letrozole

In a postnatal developmental toxicity study in lactating rats, letrozole was administered orally at doses of 1, 0.003, 0.03 or 0.3 mg/kg/day on Day 0 through Day 20 of lactation. The reproductive performance of the male offspring was impaired at a letrozole dose as low as 0.003 mg/kg/day (approximately 0.01 the MRHD on a mg/m² basis), as reflected by decreased mating and pregnancy ratios. There were no effects on the reproductive performance of female offspring.

8.3 Females and Males of Reproductive Potential

Based on animal studies and mechanisms of action, KISQALI FEMARA CO-PACK can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

Pregnancy Testing

Verify pregnancy status in females of reproductive potential prior to starting treatment with KISQALI FEMARA CO-PACK.

Contraception

Females

Advise females of reproductive potential to use effective contraception (methods that result in less than 1% pregnancy rates) during treatment with KISQALI FEMARA CO-PACK and for at least 3 weeks after the last dose.
Infertility

Females
Based on studies with letrozole in female animals, KISQALI FEMARA CO-PACK may impair fertility in females of reproductive potential [see Nonclinical Toxicology (13.1)].

Males
Based on animal studies in males, KISQALI FEMARA CO-PACK may impair fertility in males of reproductive potential [see Nonclinical Toxicology (13.1)].

8.4 Pediatric Use
The safety and efficacy of KISQALI FEMARA CO-PACK in pediatric patients have not been established.

Letrozole administration to young (postnatal Day 7) rats for 12 weeks duration at 0.003, 0.03, 0.3 mg/kg/day by oral gavage resulted in adverse skeletal/growth effects (bone maturation, bone mineral density) and neuroendocrine and reproductive developmental perturbations of the hypothalamic-pituitary axis. Administration of 0.3 mg/kg/day resulted in AUC values that were similar to the AUC in adult patients receiving the recommended dose of 2.5 mg/day. Decreased fertility was accompanied by hypertrophy of the hypophysis and testicular changes that included degeneration of the seminiferous tubular epithelium and atrophy of the female reproductive tract. Young rats in this study were allowed to recover following discontinuation of letrozole treatment for 42 days. Histopathological changes were not reversible at clinically relevant exposures.

8.5 Geriatric Use
Of 334 patients who received KISQALI plus letrozole in MONALEESA-2, 150 patients (45%) were ≥ 65 years of age and 35 patients (11%) were ≥ 75 years of age. No overall differences in safety or effectiveness of KISQALI plus letrozole were observed between these patients and younger patients. Of 248 patients who received KISQALI in MONALEESA-7, no patients were ≥ 65 years of age.

8.6 Hepatic Impairment
No dose adjustment of KISQALI is necessary in patients with mild hepatic impairment (Child-Pugh class A). The recommended starting dose is 400 mg KISQALI once daily for patients with moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C) [see Clinical Pharmacology (12.3)].

No dose adjustment of FEMARA is necessary in patients with mild (Child-Pugh class A) to moderate (Child-Pugh class B) hepatic impairment. The dose of FEMARA in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50% [see Clinical Pharmacology (12.3)]. The recommended dose of FEMARA for such patients is 2.5 mg administered every other day. The effect of hepatic impairment on FEMARA exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined [see Clinical Pharmacology (12.3)].

8.7 Renal Impairment
Based on a population pharmacokinetic analysis, no dose adjustment of KISQALI is necessary in patients with mild (60 mL/min/1.73 m² ≤ estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m²) or moderate (30 mL/min/1.73 m² ≤ eGFR < 60 mL/min/1.73 m²) renal impairment. Based on a ribociclib renal impairment study in healthy subjects and non-cancer subjects with severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m²), a starting dose of 200 mg of KISQALI is recommended. KISQALI has not been studied in breast cancer patients with severe renal impairment [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)].

No dosage adjustment of FEMARA is required for patients with renal impairment if creatinine clearance is greater than or equal to 10 mL/min [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)].

10 OVERDOSAGE
There is limited experience with reported cases of overdose with ribociclib and letrozole in MONALEESA-2 and MONALEESA-7. General symptomatic and supportive measures should be initiated in all cases of overdose where necessary.

Refer to the Full Prescribing Information of FEMARA for additional overdosage information.
11 DESCRIPTION

KISQALI FEMARA CO-PACK consists of ribociclib 200 mg film-coated tablets copackaged with letrozole 2.5 mg tablets.

Ribociclib

KISQALI (ribociclib) is a kinase inhibitor.

Ribociclib succinate is a light yellow to yellowish brown crystalline powder. The chemical name of ribociclib succinate is: Butanedioic acid—7-cyclopentyl-N,N-dimethyl-2-\{(5-(piperazin-1-yl) pyridin-2-yl)amino\}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (1/1).

The molecular formula for ribociclib succinate is C_{23}H_{30}N_{8}O.C_{4}H_{6}O_{4} and the molecular weight is 552.64 g/mol \[\text{Free base: 434.55 g/mol}\].

The chemical structure of ribociclib is shown below:

\[
\text{Chemical Structure Image}
\]

KISQALI film-coated tablets are supplied for oral use and contain 200 mg of ribociclib free base (equivalent to 254.40 mg ribociclib succinate). The tablets also contain colloidal silicon dioxide, crospovidone, hydroxypropylcellulose, magnesium stearate, and microcrystalline cellulose. The film-coating contains iron oxide black, iron oxide red, lecithin (soya), polyvinyl alcohol (partially hydrolyzed), talc, titanium dioxide, and xanthan gum as inactive ingredients.

Letrozole

FEMARA (letrozole) is a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis).

Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water. It has a molecular weight of 285.31 g/mol, empirical formula C_{17}H_{11}N_{5}, and a melting range of 184°C to 185°C.

The chemical name of letrozole is 4,4’-(1H-1,2,4-Triazol-1ylmethylene) dibenzonitrile, and its structural formula is

\[
\text{Chemical Structure Image}
\]

FEMARA is available as 2.5 mg tablets for oral administration.

Inactive Ingredients: colloidal silicon dioxide, ferric oxide, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, maize starch, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, talc, and titanium dioxide.
12.1 Mechanism of Action

Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and play a crucial role in signaling pathways, which lead to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb).

In vitro, ribociclib decreased pRb phosphorylation leading to arrest in the G1 phase of the cell cycle and reduced cell proliferation in breast cancer cell lines. In vivo, treatment with single agent ribociclib in a rat xenograft model with human tumor cells led to decreased tumor volumes, which correlated with inhibition of pRb phosphorylation.

Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.

In vivo studies, using patient-derived estrogen receptor positive breast cancer xenograft models, combination of ribociclib and antiestrogen (e.g., letrozole) resulted in increased tumor growth inhibition compared to each drug alone.

12.2 Pharmacodynamics

Ribociclib

Cardiac Electrophysiology

Serial, triplicate ECGs were collected following a single dose and at steady-state to evaluate the effect of ribociclib on the QTcF interval in patients with advanced cancer. A pharmacokinetic-pharmacodynamic analysis included a total of 997 patients treated with ribociclib at doses ranging from 50 to 1200 mg. The analysis suggested that ribociclib causes concentration-dependent increases in the QTcF interval. The estimated mean change from baseline in QTcF for KISQALI 600 mg in combination with aromatase inhibitors was 22.0 ms (90% CI: 22.0, 23.4) at the geometric mean C\text{max} at steady-state [see Warnings and Precautions (5.3)].

Letrozole

In postmenopausal patients with advanced breast cancer, daily doses of 0.1 mg to 5 mg FEMARA (letrozole) suppress plasma concentrations of estradiol, estrone, and estrone sulfate by 75% to 95% from baseline with maximal suppression achieved within two-three days. Suppression is dose-related, with doses of 0.5 mg and higher giving many values of estrone and estrone sulfate that were below the limit of detection in the assays. Estrogen suppression was maintained throughout treatment in all patients treated at 0.5 mg or higher.

Letrozole is highly specific in inhibiting aromatase activity. There is no impairment of adrenal steroidogenesis. No clinically relevant changes were found in the plasma concentrations of cortisol, aldosterone, 11-deoxycortisol, 17-hydroxy-progesterone, adrenocorticotropic hormone (ACTH) or in plasma renin activity among postmenopausal patients treated with a daily dose of FEMARA 0.1 mg to 5 mg. The ACTH stimulation test performed after 6 and 12 weeks of treatment with daily doses of 0.1, 0.25, 0.5, 1, 2.5, and 5 mg did not indicate any attenuation of aldosterone or cortisol production. Glucocorticoid or mineralocorticoid supplementation is, therefore, not necessary.

No changes were noted in plasma concentrations of androgens (androstenedione and testosterone) among healthy postmenopausal women after 0.1, 0.5, and 2.5 mg single doses of FEMARA or in plasma concentrations of androstenedione among postmenopausal patients treated with daily doses of 0.1 mg to 5 mg. This indicates that the blockade of estrogen biosynthesis does not lead to accumulation of androgenic precursors. Plasma levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were not affected by letrozole in patients, nor was thyroid function as evaluated by thyroid stimulating hormone (TSH) levels, T3 uptake, and T4 levels.

12.3 Pharmacokinetics

Ribociclib exhibited over-proportional increases in exposure (peak plasma concentrations (C\text{max}) and area under the time concentration curve (AUC)) across the dose range of 50 mg to 1200 mg following both single dose and repeated doses. Following repeated 600 mg once daily administration, steady-state was generally achieved after 8 days and ribociclib accumulated with a geometric mean accumulation ratio of 2.51 (range, 0.972 to 6.40).
Letrozole's terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2-6 weeks. Plasma concentrations at steady state are 1.5 to 2 times higher than predicted from the concentrations measured after a single dose, indicating a slight non-linearity in the pharmacokinetics of letrozole upon daily administration of 2.5 mg. These steady-state levels are maintained over extended periods, however, and continuous accumulation of letrozole does not occur.

**Absorption and Distribution**

**Ribociclib**

The time to reach $C_{\text{max}}$ ($T_{\text{max}}$) following ribociclib administration was between 1 and 4 hours. The mean absolute bioavailability of ribociclib after a single oral dose of 600 mg was 65.8%.

Binding of ribociclib to human plasma proteins *in vitro* was approximately 70% and independent of concentration (10 to 10,000 ng/mL). Ribociclib was equally distributed between red blood cells and plasma with a mean *in vivo* blood-to-plasma ratio of 1.04. The apparent volume of distribution at steady-state ($V_{\text{ss/F}}$) was 1090 L based on population PK analysis.

*Food Effect:* Compared to the fasted state, oral administration of a single 600 mg dose of KISQALI film-coated tablet with a high-fat, high-calorie meal (approximately 800 to 1000 calories with ~50% calories from fat, ~35% calories from carbohydrates, and ~15% calories from protein) had no effect on the rate and extent of absorption of ribociclib ($C_{\text{max}}$ GMR: 1.00; 90% CI: 0.898, 1.11; $AUC_{\text{inf}}$ GMR: 1.06; 90% CI: 1.01, 1.12).

**Letrozole**

Letrozole is rapidly and completely absorbed from the gastrointestinal tract and absorption is not affected by food. It is metabolized slowly to an inactive metabolite whose glucuronide conjugate is excreted renally, representing the major clearance pathway. About 90% of radiolabeled letrozole is recovered in urine.

Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).

**Metabolism and Elimination/Excretion**

**Ribociclib**

*In vitro* and *in vivo* studies indicated ribociclib undergoes extensive hepatic metabolism mainly via CYP3A4 in humans. Following oral administration of a single 600 mg dose of radiolabeled ribociclib to humans, the primary metabolic pathways for ribociclib involved oxidation (dealkylation, C and/or N-oxygenation, oxidation (-2H)) and combinations thereof. Phase II conjugates of ribociclib Phase I metabolites involved N-acetylation, sulfation, cysteine conjugation, glycosylation, and glucuronidation. Ribociclib was the major circulating drug-derived entity in plasma (44%). The major circulating metabolites included metabolite M13 (CCI284, N-hydroxylation), M4 (LEQ803, N-demethylation), and M1 (secondary glucuronide), each representing an estimated 9%, 9%, and 8% of total radioactivity, and 22%, 20%, and 18% of ribociclib exposure. Clinical activity (pharmacological and safety) of ribociclib was due primarily to parent drug, with negligible contribution from circulating metabolites.

Ribociclib was extensively metabolized with unchanged drug accounting for 17% and 12% in feces and urine, respectively. Metabolite LEQ803 was a significant metabolite in excreta and represented approximately 14% and 4% of the administered dose in feces and urine, respectively. Numerous other metabolites were detected in both feces and urine in minor amounts (≤ 3% of the administered dose).

The geometric mean plasma effective half-life (based on accumulation ratio) was 32.0 hours (63% CV) and the geometric mean apparent oral clearance ($CL/F$) was 25.5 L/hr (66% CV) at steady-state at 600 mg in patients with advanced cancer. The geometric mean apparent plasma terminal half-life ($T_{1/2}$) of ribociclib ranged from 29.7 to 54.7 hours and geometric mean $CL/F$ of ribociclib ranged from 39.9 to 77.5 L/hr at 600 mg across studies in healthy subjects.

Ribociclib is eliminated mainly via feces, with a small contribution of the renal route. In 6 healthy male subjects, following a single oral dose of radiolabeled ribociclib, 92% of the total administered radioactive dose was recovered within 22 days; feces was the major route of excretion (69%), with 23% of the dose recovered in urine.

**Letrozole**

Metabolism to a pharmacologically-inactive carbinol metabolite (4,4'methanol-bisbenzonitrile) and renal excretion of the glucuronide conjugate of this metabolite is the major pathway of letrozole clearance. Of the radiolabel recovered in urine, at least 75% was the glucuronide of the carbinol metabolite, about 9% was two unidentified metabolites, and 6% was unchanged letrozole.
In human microsomes with specific CYP isozyme activity, CYP3A4 metabolized letrozole to the carbinol metabolite while CYP2A6 formed both this metabolite and its ketone analog. In human liver microsomes, letrozole inhibited CYP2A6 and inhibited CYP2C19, however, the clinical significance of these findings is unknown.

Specific Populations

Patients with Hepatic Impairment

Ribociclib

Based on a pharmacokinetic trial in patients with hepatic impairment, mild (Child-Pugh class A) hepatic impairment had no effect on the exposure of ribociclib. The mean exposure for ribociclib was increased less than 2-fold in patients with moderate (Child-Pugh class B; geometric mean ratio [GMR]: 1.44 for C\text{max}; 1.28 for AUC\text{inf}) or severe (Child-Pugh class C; GMR: 1.32 for C\text{max}; 1.29 for AUC\text{inf}) hepatic impairment. Based on a population pharmacokinetic analysis that included 160 patients with normal hepatic function and 47 patients with mild hepatic impairment, mild hepatic impairment had no effect on the exposure of ribociclib, further supporting the findings from the dedicated hepatic impairment study.

Letrozole

In a study of subjects with mild to moderate non-metastatic hepatic dysfunction (e.g., cirrhosis, Child-Pugh class A and B), the mean AUC values of the volunteers with moderate hepatic impairment were 37% higher than in normal subjects, but still within the range seen in subjects without impaired function.

In a pharmacokinetic study, subjects with liver cirrhosis and severe hepatic impairment (Child-Pugh class C, which included bilirubins about 2-11 times ULN with minimal to severe ascites) had 2-fold increase in exposure (AUC) and 47% reduction in systemic clearance. Breast cancer patients with severe hepatic impairment are thus expected to be exposed to higher levels of letrozole than patients with normal liver function receiving similar doses of this drug [see Clinical Pharmacology (12.3)].

Patients with Renal Impairment

Ribociclib

The effect of renal impairment on the pharmacokinetics of ribociclib was assessed in a renal impairment study in non-cancer subjects with normal renal function (eGFR ≥ 90 mL/min/1.73 m$^2$, n = 9), severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m$^2$, n = 6), and End Stage Renal Disease (ESRD) (eGFR < 15 mL/min/1.73 m$^2$, n = 4) at a single ribociclib dose of 400 mg/day. In subjects with severe renal impairment and ESRD, AUC\text{inf} increased 2.37-fold and 3.81-fold, and C\text{max} increased 2.10-fold and 2.68-fold relative to the exposure in non-cancer study participants with normal renal function. Mild (60 mL/min/1.73 m$^2$ ≤ eGFR < 90 mL/min/1.73 m$^2$) or moderate (30 mL/min/1.73 m$^2$ ≤ eGFR < 60 mL/min/1.73 m$^2$) renal impairment had no effect on the exposure of ribociclib based on a population PK analysis that included 438 cancer patients with normal renal function, 488 patients with mild renal impairment and 113 patients with moderate renal impairment. In addition, in a sub-group analysis of data from studies following oral administration of ribociclib 600 mg as a single dose or repeat doses in cancer patients with mild or moderate renal impairment, AUC and C\text{max} were comparable to patients with normal renal function, suggesting no clinically meaningful effect of mild or moderate renal impairment on ribociclib exposure.

Letrozole

In a study of volunteers with varying renal function (24-hour creatinine clearance: 9 to 116 mL/min), no effect of renal function on the pharmacokinetics of single doses of 2.5 mg of FEMARA was found. In addition, in a study of 347 patients with advanced breast cancer, about half of whom received 2.5 mg FEMARA and half 0.5 mg FEMARA, renal impairment (calculated creatinine clearance: 20 to 50 mL/min) did not affect steady-state plasma letrozole concentrations.

Additional Pharmacokinetic Information on Ribociclib:

The pharmacokinetics of ribociclib was investigated in patients with advanced cancer following oral daily doses ranging from 50 mg to 1200 mg. Healthy subjects received single oral doses of 400 or 600 mg or repeated daily oral doses (8 days) at 400 mg.
Effect of Age, Weight, Gender, and Race

Population PK analysis showed that there are no clinically relevant effects of age, body weight, gender, or race on the systemic exposure of ribociclib.

Drug Interaction Studies

Drugs That Affect Ribociclib Plasma Concentrations

CYP3A Inhibitors: A drug interaction trial in healthy subjects was conducted with ritonavir (a strong CYP3A inhibitor). Compared to ribociclib alone, ritonavir (100 mg twice a day for 14 days) increased ribociclib $C_{\text{max}}$ and $AUC_{\text{inf}}$ by 1.7-fold and 3.2-fold, respectively, following a single 400 mg ribociclib dose. $C_{\text{max}}$ and $AUC$ for LEQ803 (a prominent metabolite of LEE011, accounting for less than 10% of parent exposure) decreased by 96% and 98%, respectively. A moderate CYP3A4 inhibitor (erythromycin) is predicted to increase ribociclib $C_{\text{max}}$ and $AUC$ by 1.3-fold and 1.9-fold, respectively.

CYP3A Inducers: A drug interaction trial in healthy subjects was conducted with rifampicin (a strong CYP3A4 inducer). Compared to ribociclib alone, rifampicin (600 mg daily for 14 days) decreased ribociclib $C_{\text{max}}$ and $AUC_{\text{inf}}$ by 81% and 89%, respectively, following a single 600 mg ribociclib dose. LEQ803 $C_{\text{max}}$ increased 1.7-fold and $AUC_{\text{inf}}$ decreased by 27%, respectively. A moderate CYP3A inducer (efavirenz) is predicted to decrease ribociclib $C_{\text{max}}$ and $AUC$ by 37% and 60%, respectively.

Drugs That Are Affected by KISQALI

CYP3A4 and CYP1A2 Substrates: A drug interaction trial in healthy subjects was conducted as a cocktail study with midazolam (sensitive CYP3A4 substrate) and caffeine (sensitive CYP1A2 substrate). Compared to midazolam and caffeine alone, multiple doses of ribociclib (400 mg once daily for 8 days) increased midazolam $C_{\text{max}}$ and $AUC_{\text{inf}}$ by 2.1-fold and 3.8-fold, respectively. Administration of ribociclib at 600 mg once daily is predicted to increase midazolam $C_{\text{max}}$ and $AUC$ by 2.4-fold and 5.2-fold, respectively. The effect of multiple doses of 400 mg ribociclib on caffeine was minimal, with $C_{\text{max}}$ decreased by 10% and $AUC_{\text{inf}}$ increased slightly by 20%. Only weak inhibitory effects on CYP1A2 substrates are predicted at 600 mg ribociclib once daily dose.

Gastric pH-Elevating Agents: Coadministration of ribociclib with drugs that elevate the gastric pH was not evaluated in a clinical trial; however, altered ribociclib absorption was not identified in a population PK analysis and was not predicted using physiology based PK models.

Letrozole: Data from a clinical trial in patients with breast cancer and population PK analysis indicated no drug interaction between ribociclib and letrozole following coadministration of the drugs.

Anastrozole: Data from a clinical trial in patients with breast cancer indicated no clinically relevant drug interaction between ribociclib and anastrozole following coadministration of the drugs.

Exemestane: Data from a clinical trial in patients with breast cancer indicated no clinically relevant drug interaction between ribociclib and exemestane following coadministration of the drugs.

Fulvestrant: Data from a clinical trial in patients with breast cancer indicated no clinically relevant effect of fulvestrant on ribociclib exposure following coadministration of the drugs.

Tamoxifen: KISQALI is not indicated for concomitant use with tamoxifen. Data from a clinical trial in patients with breast cancer indicated that tamoxifen $C_{\text{max}}$ and $AUC$ increased approximately 2-fold following coadministration of 600 mg ribociclib.

In Vitro Studies

Effect of Ribociclib on CYP Enzymes: In vitro, ribociclib was a reversible inhibitor of CYP1A2, CYP2E1, and CYP3A4/5 and a time-dependent inhibitor of CYP3A4/5, at clinically relevant concentrations. In vitro evaluations indicated that KISQALI has no potential to inhibit the activities of CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 at clinically relevant concentrations. It has no potential for time-dependent inhibition of CYP1A2, CYP2C9, and CYP2D6, and no induction of CYP1A2, CYP2B6, CYP2C9, and CYP3A4 at clinically relevant concentrations.

Effect of Ribociclib on Transporters: In vitro evaluations indicated that KISQALI has a low potential to inhibit the activities of drug transporters P-gp, OATP1B1/B3, OCT1, MATEK2 at clinically relevant concentrations. KISQALI may inhibit BCRP, OCT2, MATE1, and human BSEP at clinically relevant concentrations.
Effect of Transporters on Ribociclib: Based on in vitro data, P-gp, and BCRP mediated transport are unlikely to affect the extent of oral absorption of ribociclib at therapeutic doses. Ribociclib is not a substrate for hepatic uptake transporters OATP1B1/1B3 or OCT-1 in vitro.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Ribociclib

In a 2-year carcinogenicity study with oral administration of ribociclib daily in cycles of 3 weeks on/1 week off, ribociclib was not carcinogenic at doses up to 50 mg/kg in male rats and 600 mg/kg in female rats. Systemic exposure in male and female rats were 1.3 and 1.8 times, respectively, the human exposure at the highest recommended dose of 600 mg/day based on AUC.

Ribociclib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay or clastogenic in an in vitro human lymphocyte chromosomal aberration assay or an in vivo rat bone marrow micronucleus assay.

In a fertility and early embryonic development study, female rats received oral doses of ribociclib for 14 days prior to mating through the first week of pregnancy. Ribociclib did not affect reproductive function, fertility or early embryonic development at doses up to 300 mg/kg/day (approximately 0.6 times the clinical exposure in patients at the highest recommended dose of 600 mg/day based on AUC).

A fertility study in male rats has not been performed with ribociclib. In repeat-dose toxicity studies with oral administration of ribociclib daily for 3 weeks on/1 week off in rats up to 26 weeks duration and dogs up to 39 weeks duration, atrophic changes in testes were reported. Findings included degeneration of seminiferous tubular epithelia in the testes and hypospermia and luminal cellular debris in the epididymides of rats and dogs and vacuolation of epithelia in the epididymides of rats. These findings were observed at doses ≥ 75 mg/kg in rats and ≥ 1 mg/kg in dogs which resulted in systemic exposures that were 1.4 and 0.03 times the human exposure at the highest recommended daily dose of 600 mg/day based on AUC, respectively. These effects can be linked to a direct anti-proliferative effect on the testicular germ cells resulting in atrophy of the seminiferous tubules and showed a trend towards reversibility in rats and dogs after a four-week, non-dosing period.

Letrozole

A conventional carcinogenesis study in mice at doses of 0.6 to 60 mg/kg/day (about 1 to 100 times the daily MRHD on a mg/m² basis) administered by oral gavage for up to 2 years revealed a dose-related increase in the incidence of benign ovarian stromal tumors. The incidence of combined hepatocellular adenoma and carcinoma showed a significant trend in females when the high dose group was excluded due to low survival. In a separate study, plasma AUC₀-₁₂₅ₐₚ levels in mice at 60 mg/kg/day were 55 times higher than the AUC₀-₂₄ₖₐₚ level in breast cancer patients at the recommended dose. The carcinogenicity study in rats at oral doses of 0.1 to 10 mg/kg/day (about 0.4 to 40 times the daily MRHD on a mg/m² basis) for up to 2 years also produced an increase in the incidence of benign ovarian stromal tumors at 10 mg/kg/day. Ovarian hyperplasia was observed in females at doses equal to or greater than 0.1 mg/kg/day. At 10 mg/kg/day, plasma AUC₀-₂₄ₖₐₚ levels in rats were 80 times higher than the level in breast cancer patients at the recommended dose. The benign ovarian stromal tumors observed in mice and rats were considered to be related to the pharmacological inhibition of estrogen synthesis and may be due to increased luteinizing hormone resulting from the decrease in circulating estrogen.

Letrozole was not mutagenic in in vitro tests (Ames and E.coli bacterial tests) but was observed to be a potential clastogen in in vitro assays [Chinese hamster ovary (CHO) K1 and CCL61 CHO cells]. Letrozole was not clastogenic in vivo (micronucleus test in rats).

In a fertility and early embryonic developmental toxicity study in female rats, oral administration of letrozole starting 2 weeks before mating until pregnancy Day 6 resulted in decreases in the incidence of successful mating and pregnancy at doses ≥ 0.03 mg/kg/day (approximately 0.1 times the recommended human dose on a mg/m² basis). In repeat-dose toxicity studies, administration of letrozole caused sexual inactivity in females and atrophy of the reproductive tract in males and females at doses of 0.6, 0.1, and 0.03 mg/kg in mice, rats and dogs, respectively (approximately 1, 0.4, and 0.4 times the daily MRHD on a mg/m² basis, respectively).
13.2 Animal Toxicology and/or Pharmacology

Ribociclib

*In vivo* cardiac safety studies in dogs demonstrated dose and concentration related QTc interval prolongation at an exposure similar to patients receiving the recommended dose of 600 mg. There is a potential to induce incidences of premature ventricular contractions (PVCs) at elevated exposures (approximately 5-fold the anticipated clinical C\textsubscript{max}).

14 CLINICAL STUDIES

MONALEESA-2: KISQALI in Combination with Letrozole

*Postmenopausal Women with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer for Initial Endocrine-Based Therapy*

MONALEESA-2 (NCT01958021) was a randomized, double-blind, placebo-controlled, multicenter clinical study of KISQALI plus letrozole vs. placebo plus letrozole conducted in postmenopausal women with HR-positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease.

A total of 668 patients were randomized to receive either KISQALI and letrozole (n = 334) or placebo and letrozole (n = 334), stratified according to the presence of liver and/or lung metastases. Letrozole 2.5 mg was given orally once daily for 28 days, with either KISQALI 600 mg or placebo orally once daily for 21 consecutive days followed by 7 days off until disease progression or unacceptable toxicity. The major efficacy outcome measure for the study was investigator-assessed progression-free survival (PFS) using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

Patients enrolled in MONALEESA-2 had a median age of 62 years (range, 23 to 91) and 45% of patients were older than 65. The majority of patients were White (82%), and all patients had an ECOG performance status of 0 or 1. A total of 47% of patients had received chemotherapy and 51% had received anti-hormonal therapy in the neoadjuvant or adjuvant setting. Thirty-four percent (34%) of patients had de novo metastatic disease, 21% had bone-only disease, and 59% had visceral disease.

The efficacy results from MONALEESA-2 are summarized in Table 12, Figure 1, and Figure 2. The PFS assessment based on a blinded independent central radiological review was consistent with investigator assessment.

Consistent results were observed across patient subgroups of prior adjuvant or neoadjuvant chemotherapy or hormonal therapies, liver and/or lung involvement, and bone-only metastatic disease.

**Table 12: Efficacy Results – MONALEESA-2 (Investigator Assessment, Intent-to-Treat Population)**

<table>
<thead>
<tr>
<th></th>
<th>KISQALI + Letrozole</th>
<th>Placebo + Letrozole</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Progression-Free Survival</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Events (%)</td>
<td>93 (27.8)</td>
<td>150 (44.9)</td>
</tr>
<tr>
<td>Median (months, 95% CI)</td>
<td>NR (19.3 – NR)</td>
<td>14.7 (13.0 – 16.5)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.556 (0.429, 0.720)</td>
<td></td>
</tr>
<tr>
<td><em>p</em>-value</td>
<td>&lt; 0.0001*</td>
<td></td>
</tr>
<tr>
<td><strong>Overall survival</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Events (%)</td>
<td>181 (54.2%)</td>
<td>219 (65.6%)</td>
</tr>
<tr>
<td>Median (months, 95% CI)</td>
<td>63.9 (52.4, 71.0)</td>
<td>51.4 (47.2, 59.7)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.765 (0.628, 0.932)</td>
<td></td>
</tr>
<tr>
<td><em>p</em>-value</td>
<td>0.004*</td>
<td></td>
</tr>
<tr>
<td><strong>Overall response rate</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with measurable disease (95% CI)</td>
<td>52.7 (46.6, 58.9)</td>
<td>37.1 (31.1, 43.2)</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; NR, not reached.

* *p*-value estimated from one-sided log-rank test.
MONALEESA-7: KISQALI in Combination with an Aromatase Inhibitor

*Pre/perimenopausal Patients with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer for Initial Endocrine-Based Therapy*

MONALEESA-7 (NCT02278120) was a randomized, double-blind, placebo-controlled study of KISQALI plus either non-steroidal aromatase inhibitor (NSAI) or tamoxifen and goserelin vs. placebo plus either a NSAI or tamoxifen and goserelin conducted in pre/perimenopausal women with HR-positive, HER2-negative, advanced breast cancer who received no prior endocrine therapy for advanced disease.
A total of 672 patients were randomized to receive KISQALI plus NSAI or tamoxifen plus goserelin (n = 335) or placebo plus NSAI or tamoxifen plus goserelin (n = 337), stratified according to the presence of liver and/or lung metastases, prior chemotherapy for advanced disease, and endocrine combination partner (tamoxifen and goserelin vs. NSAI and goserelin). Among 248 patients who received KISQALI plus NSAI plus goserelin, 211 (85%) received letrozole and 37 (15%) received anastrozole.

NSAI (letrozole 2.5 mg or anastrozole 1 mg) or tamoxifen 20 mg were given orally once daily on a continuous daily schedule, goserelin was administered as a sub-cutaneous injection on Day 1 of each 28-day cycle, with either KISQALI 600 mg or placebo orally once daily for 21 consecutive days followed by 7 days off until disease progression or unacceptable toxicity. The major efficacy outcome measure for the study was investigator-assessed progression-free survival (PFS) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Patients enrolled in MONALEESA-7 had a median age of 44 years (range, 25 to 58) and were primarily White (58%), Asian (29%), or Black (3%). Nearly all patients (99%) had an ECOG performance status of 0 or 1. Of the 672 patients, 33% had received chemotherapy in the adjuvant vs. 18% in the neoadjuvant setting and 40% had received endocrine therapy in the adjuvant vs. 0.7% in the neoadjuvant setting prior to study entry. Forty percent (40%) of patients had de novo metastatic disease, 24% had bone-only disease, and 57% had visceral disease. Demographics and baseline disease characteristics were balanced and comparable between study arms, and endocrine combination partner.

The efficacy results from a pre-specified subgroup analysis of 495 patients who had received KISQALI or placebo with NSAI plus goserelin are summarized in Table 13, Figure 3, and Figure 4. Consistent results were observed in the stratification factor subgroups of disease site and prior chemotherapy for advanced disease.

<table>
<thead>
<tr>
<th>Table 13: Efficacy Results – MONALEESA-7 (NSAI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KISQALI + NSAI + Goserelin</td>
</tr>
<tr>
<td><strong>Progression-free survival¹</strong></td>
</tr>
<tr>
<td>Events (n, %)</td>
</tr>
<tr>
<td>Median (months, 95% CI)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
</tr>
<tr>
<td><strong>Overall survival</strong></td>
</tr>
<tr>
<td>Events (n, %)</td>
</tr>
<tr>
<td>Median (months, 95% CI)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
</tr>
<tr>
<td><strong>Overall response rate*¹</strong></td>
</tr>
<tr>
<td>Patients with measurable disease (95% CI)</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; NR, not reached; NSAI, non-steroidal aromatase inhibitors.
*Based on confirmed responses.
¹Investigator Assessment.
COMPLEEMENT-1: KISQALI in combination with Letrozole and Goserelin or Leuprolide

Men with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer for Initial Endocrine-Based Therapy

COMPLEEMENT-1 (NCT 02941926) was an open-label, multicenter clinical study of ribociclib in combination with letrozole and goserelin or leuprolide for the treatment of adults with HR-positive, HER2-negative, advanced breast cancer who received no prior hormonal therapy for advanced disease.
The study included 39 male patients who received KISQALI 600 mg orally once daily for 21 consecutive days followed by 7 days off; and letrozole 2.5 mg orally once daily for 28 days; and goserelin 3.6 mg as injectable subcutaneous implant or leuprolide 7.5 mg as intramuscular injection administered on Day 1 of each 28-day cycle. Patients were treated until disease progression or unacceptable toxicity occurred.

Male patients enrolled in this study had a median age of 62 years (range, 33 to 80). Of these patients, 39% were 65 years and older, including 10% aged 75 years and older. The male patients enrolled were White (72%), Asian (8%), and Black (3%), with 17% unknown. Nearly all male patients (97%) had an ECOG performance status of 0 or 1. The majority of male patients (97%) had 4 or less metastatic sites, which were primarily bone and visceral (69% each). Table 17 summarizes the efficacy results in male patients from COMPLEEMENT-1.

**Table 14: Efficacy Results in Male Patients**

<table>
<thead>
<tr>
<th>Overall Response Rate*2</th>
<th>N = 32</th>
</tr>
</thead>
<tbody>
<tr>
<td>(95% CI)</td>
<td>46.9 (29.1, 65.3)</td>
</tr>
<tr>
<td>Duration of Response (DoR)3</td>
<td>N = 15</td>
</tr>
<tr>
<td>Median (months, 95% CI)</td>
<td>NR (21.3, NR)</td>
</tr>
<tr>
<td>Patients with DoR ≥ 12 months, n (%)</td>
<td>12 (80.0%)</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI, confidence interval, NR, not reached.
*Based on confirmed responses.
1 Patients with measurable disease.
2 Investigator Assessment.
3 Patients with complete response or partial response.

### 16 HOW SUPPLIED/STORAGE AND HANDLING

KISQALI FEMARA CO-PACK is dispensed in a carton for a total of 28 days of therapy. Each carton contains individual ribociclib and letrozole drug products as follows:

**KISQALI (ribociclib) Tablets:**

- 200 mg tablets.
- Light greyish violet, round, curved with beveled edge, debossed with “RIC” on one side and “NVR” on the other side.

**FEMARA (letrozole) Tablets:**

- 2.5 mg tablets.
- Dark yellow, round, slightly biconvex, with beveled edges, imprinted with the letters “FV” on one side and “CG” on the other side.

**KISQALI FEMARA CO-PACK Cartons:**

- NDC 0078-0923-61 – Carton of 3 blister packs (63 tablets total) – each blister pack contains a 7-day supply of 21 tablets (200 mg per tablet) (600 mg daily dose) of KISQALI plus one 28-tablet count bottle of FEMARA
- NDC 0078-0916-61 – Carton of 3 blister packs (42 tablets total) – each blister pack contains a 7-day supply of 14 tablets (200 mg per tablet) (400 mg daily dose) of KISQALI plus one 28-tablet count bottle of FEMARA
- NDC 0078-0909-61 – Carton of 1 blister pack (21 tablets total) – each blister pack contains a 21-day supply of 21 tablets (200 mg per tablet) (200 mg daily dose) of KISQALI plus one 28-tablet count bottle of FEMARA

Store KISQALI FEMARA CO-PACK at 20°C to 25°C (68°F to 77°F). Store in the original package.

### 17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

For additional information on KISQALI and FEMARA, refer to the full prescribing information for each product.

**Interstitial Lung Disease/Pneumonitis**

Advise patients to immediately report new or worsening respiratory symptoms [see Warnings and Precautions (5.1)].
Severe Cutaneous Adverse Reactions
Inform patients of the signs and symptoms of severe cutaneous adverse reactions (e.g., skin pain/burning, rapidly-spreading skin rash, and/or mucosal lesions accompanied by fever or flu-like symptoms). Advise patients to contact their healthcare provider immediately if they develop signs and symptoms of severe cutaneous adverse reactions [see Warnings and Precautions (5.2)].

QT Prolongation
Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately for signs or symptoms of QT prolongation [see Warnings and Precautions (5.3)].

Hepatobiliary Toxicity
Inform patients of the signs and symptoms of hepatobiliary toxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatobiliary toxicity [see Warnings and Precautions (5.4)].

Neutropenia
Advise patients of the possibility of developing neutropenia and to immediately contact their healthcare provider should they develop a fever, particularly in association with any suggestion of infection [see Warnings and Precautions (5.5)].

Embryo-Fetal Toxicity
Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during KISQALI FEMARA CO-PACK therapy and for at least 3 weeks after the last dose. Advise females to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, during treatment with KISQALI FEMARA CO-PACK [see Warnings and Precautions (5.6), Use in Specific Populations (8.1, 8.3)].

Lactation
Advise women not to breastfeed during KISQALI FEMARA CO-PACK treatment and for at least 3 weeks after the last dose [see Use in Specific Populations (8.2)].

Drug Interactions
- Inform patients to avoid grapefruit or grapefruit juice while taking KISQALI FEMARA CO-PACK [see Drug Interactions (7.1)].
- Inform patients to avoid strong CYP3A inhibitors, strong CYP3A inducers, and drugs known to prolong the QT interval [see Drug Interactions (7.1, 7.2, 7.4)].

Infertility
Inform males of reproductive potential that KISQALI may impair fertility [see Use in Specific Populations (8.3)].

Dosing
- Instruct patients to take the doses of KISQALI FEMARA CO-PACK at approximately the same time every day and to swallow tablets whole (do not chew, crush, or split them prior to swallowing) [see Dosage and Administration (2.1)].
- If patient vomits or misses a dose, advise the patient to take the next prescribed dose at the usual time [see Dosage and Administration (2.1)].
- Advise the patient that KISQALI FEMARA CO-PACK may be taken with or without food [see Dosage and Administration (2.1)].
What is the most important information I should know about KISQALI FEMARA CO-PACK?

KISQALI FEMARA CO-PACK may cause serious side effects, including:

- **Lung problems.** KISQALI may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms, including:
  - trouble breathing or shortness of breath
  - cough with or without mucus
  - chest pain

- **Severe skin reactions.** Tell your healthcare provider or get medical help right away if you get severe rash or rash that keeps getting worse, reddened skin, flu-like symptoms, skin pain/burning, blistering of the lips, eyes or mouth, blisters on the skin or skin peeling, with or without fever.

- **Heart rhythm problems (QT prolongation).** KISQALI FEMARA CO-PACK can cause a heart problem known as QT prolongation. This condition can cause an abnormal heartbeat and may lead to death. Your healthcare provider should check your heart and do blood tests before and during treatment with KISQALI FEMARA CO-PACK. Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you feel dizzy or faint.

- **Liver problems.** KISQALI FEMARA CO-PACK can cause serious liver problems. Your healthcare provider will do blood tests to check your liver before you start and while you take KISQALI FEMARA CO-PACK. Tell your healthcare provider right away if you get any of the following signs and symptoms of liver problems:
  - yellowing of your skin or the whites of your eyes (jaundice)
  - dark or brown (tea-colored) urine
  - feeling very tired
  - loss of appetite
  - pain on the upper right side of your stomach area (abdomen)
  - bleeding or bruising more easily than normal

- **Low white blood cell counts (neutropenia).** Low white blood cell counts are very common during treatment with KISQALI FEMARA CO-PACK and may result in infections that may be severe. Your healthcare provider should check your white blood cell counts before and during treatment with KISQALI FEMARA CO-PACK. Tell your healthcare provider right away if you have signs and symptoms of low white blood cell counts or infections, such as fever and chills.

Your healthcare provider may tell you to decrease your dose, temporarily stop or completely stop taking KISQALI if you develop certain serious side effects during treatment with KISQALI.

See “What are the possible side effects of KISQALI FEMARA CO-PACK?” for more information about side effects.

What is KISQALI FEMARA CO-PACK?

- KISQALI FEMARA CO-PACK is a prescription medicine used as the first hormonal-based therapy to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic).

- KISQALI FEMARA CO-PACK contains 2 different types of medicines:
  - The violet tablet contains the medicine KISQALI (ribociclib).
  - The yellow tablet contains the medicine FEMARA (letrozole).

It is not known if KISQALI FEMARA CO-PACK is safe and effective in children.

Do not take KISQALI FEMARA CO-PACK if you are allergic to letrozole or any of the ingredients of FEMARA.

See the end of this Patient Information for a list of the ingredients in KISQALI FEMARA CO-PACK.

Before taking KISQALI FEMARA CO-PACK, tell your healthcare provider about all your medical conditions, including if you:

- have any heart problems, including heart failure, irregular heartbeats, and QT prolongation
- have ever had a heart attack
- have a slow heartbeat (bradycardia)
- have problems with the amount of potassium, calcium, phosphorus, or magnesium in your blood
- have fever, chills, or any other signs or symptoms of infection
- have liver problems
- are pregnant, or plan to become pregnant. KISQALI FEMARA CO-PACK can harm your unborn baby.

  - If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with KISQALI FEMARA CO-PACK.
Females who are able to become pregnant and who take KISQALI FEMARA CO-PACK should use effective birth control during treatment and for at least 3 weeks after the last dose of KISQALI FEMARA CO-PACK.

- Talk to your healthcare provider about birth control methods that may be right for you during this time.
- If you become pregnant or think you are pregnant, tell your healthcare provider right away.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. KISQALI FEMARA CO-PACK and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How should I take KISQALI FEMARA CO-PACK?

- Take KISQALI FEMARA CO-PACK exactly as your healthcare provider tells you.
- Do not change your dose or stop taking KISQALI FEMARA CO-PACK unless your healthcare provider tells you.
- KISQALI FEMARA CO-PACK comes in a carton that contains enough KISQALI tablets and FEMARA tablets for 28 days of treatment.
- Take KISQALI FEMARA CO-PACK each day at about the same time, preferably in the morning.
- Take KISQALI FEMARA CO-PACK with food or without food.
- Swallow KISQALI tablets and FEMARA tablets whole. Do not chew, crush or split tablets before swallowing them.
- Do not take any KISQALI tablets and FEMARA tablets that are broken, cracked, or that look damaged.
- If you miss a dose or vomit after taking a dose of KISQALI FEMARA CO-PACK, do not take another dose on that day. Take your next dose at your regular time.
- If you take too much KISQALI FEMARA CO-PACK, call your healthcare provider right away or go to the nearest hospital emergency room.

What should I avoid while taking KISQALI FEMARA CO-PACK?

- Avoid eating grapefruit and avoid drinking grapefruit juice during treatment with KISQALI FEMARA CO-PACK since these may increase the amount of KISQALI in your blood.

What are the possible side effects of KISQALI FEMARA CO-PACK?

KISQALI FEMARA CO-PACK may cause serious side effects.

- See "What is the most important information I should know about KISQALI FEMARA CO-PACK?"

The most common side effects of KISQALI FEMARA CO-PACK include:

- decreased white blood cell counts
- decreased red blood cell counts
- abnormal liver function tests
- infections
- nausea
- tiredness
- decreased platelet counts
- diarrhea
- headache
- hair loss
- vomiting
- back pain
- constipation
- cough
- rash
- increased kidney function test
- stomach-area (abdomen) pain

KISQALI FEMARA CO-PACK may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a problem for you.

These are not all of the possible side effects of KISQALI FEMARA CO-PACK.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store KISQALI FEMARA CO-PACK?

- Store KISQALI FEMARA CO-PACK at 68°F to 77°F (20°C to 25°C).
- Keep KISQALI FEMARA CO-PACK in its original container.

Keep KISQALI FEMARA CO-PACK and all medicines out of the reach of children.

General information about the safe and effective use of KISQALI FEMARA CO-PACK.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use KISQALI FEMARA CO-PACK for a condition for which it was not prescribed. Do not give KISQALI FEMARA CO-PACK to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for more information about KISQALI FEMARA CO-PACK that is written for health professionals.
What are the ingredients in KISQALI FEMARA CO-PACK?

**KISQALI (ribociclib) tablets:**
- **Active ingredient:** ribociclib
- **Inactive ingredients:** colloidal silicon dioxide, crospovidone, hydroxypropylcellulose, magnesium stearate and microcrystalline cellulose. The film-coating contains iron oxide black, iron oxide red, lecithin (soya), polyvinyl alcohol (partially hydrolyzed), talc, titanium dioxide, and xanthan gum

**FEMARA (letrozole) tablets:**
- **Active ingredient:** letrozole
- **Inactive ingredients:** colloidal silicon dioxide, ferric oxide, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, maize starch, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, talc, and titanium dioxide

Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936
© Novartis
For more information, go to www.KISQALI.com or call 1-844-KISQALI (1-844-547-7254).

This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: August 2023